BRIEF-Glycomimetics' GMI-1271 yields high remission rates in phase 1 portion of phase 1/2 clinical trial for AML By: Reuters: Company News June 10, 2016 at 06:11 AM EDT * Dose escalation is complete and a GMI-1271 dose was identified for phase 2 testing Read More >> Related Stocks: Glycomimetics Inc